Suppr超能文献

静脉注射双膦酸盐对大鼠的急性肾脏影响。

Acute renal effects of intravenous bisphosphonates in the rat.

作者信息

Pfister Thomas, Atzpodien Elke, Bohrmann Bernd, Bauss Frieder

机构信息

Preclinical Research and Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

出版信息

Basic Clin Pharmacol Toxicol. 2005 Dec;97(6):374-81. doi: 10.1111/j.1742-7843.2005.pto_160.x.

Abstract

Bisphosphonates are potent osteoclast inhibitors that have been associated with renal toxicity following rapid intravenous administration of high doses, which was hypothesised to be due to precipitation of bisphosphonate aggregates or complexes in the kidney. Five studies were conducted in rats investigating the characteristics of bisphosphonate-related acute renal effects. These studies included single intravenous injections of the nitrogen-containing bisphosphonates (1) ibandronate (1-20 mg/kg), or (2) zoledronate (1-10 mg/kg); (3) a single nephrotoxic dose of the non-nitrogen-containing bisphosphonate, clodronate (2 x 200 mg/kg intraperitoneal injection); (4) a single low dose of ibandronate (1 mg/kg); (5) a single high dose of zoledronate (10 mg/kg). Clinical biochemistry and kidney histopathology were performed 1 and/or 4 days after bisphosphonate dosing. The proximal convoluted tubules were the primary target for renal injury. Tubular degeneration and single cell necrosis of the these tubules were observed with all three bisphosphonates on the fourth, but not the first day after dosing. Differences between the bisphosphonates in the type and/or localisation of the lesions were apparent. Granular deposits in the lumen of distal tubules were apparent with the highest dose of zoledronate (10 mg/kg). However, intraluminal debris was proteinaceous with no evidence of any precipitation of bisphosphonate, or formation of aggregates or complexes in the kidney. Generally, biochemical parameters of renal safety and urinary enzymes did not differ significantly from controls. In summary, bisphosphonate-related renal changes did not appear to be due to the precipitation, aggregation or complexation of bisphosphonate, and biochemical parameters of renal safety did not reliably detect this renal injury.

摘要

双膦酸盐是强效破骨细胞抑制剂,在大剂量快速静脉给药后与肾毒性有关,据推测这是由于双膦酸盐聚集体或复合物在肾脏中沉淀所致。在大鼠中进行了五项研究,以调查双膦酸盐相关急性肾效应的特征。这些研究包括单次静脉注射含氮双膦酸盐:(1)伊班膦酸钠(1 - 20 mg/kg),或(2)唑来膦酸(1 - 10 mg/kg);(3)单次给予非含氮双膦酸盐氯膦酸二钠肾毒性剂量(腹腔注射2×200 mg/kg);(4)单次低剂量伊班膦酸钠(1 mg/kg);(5)单次高剂量唑来膦酸(10 mg/kg)。在双膦酸盐给药后1天和/或4天进行临床生化检查和肾脏组织病理学检查。近端曲管是肾损伤的主要靶点。在给药后第4天而非第1天,观察到所有三种双膦酸盐均导致这些肾小管的管状变性和单细胞坏死。双膦酸盐之间在损伤类型和/或定位上存在明显差异。在唑来膦酸最高剂量(10 mg/kg)时,远端小管管腔内可见颗粒状沉积物。然而,管腔内碎片为蛋白质性,没有双膦酸盐沉淀、聚集体或复合物形成的证据。一般来说,肾脏安全性的生化参数和尿酶与对照组相比无显著差异。总之,双膦酸盐相关的肾脏变化似乎并非由于双膦酸盐的沉淀、聚集或络合,并且肾脏安全性的生化参数不能可靠地检测到这种肾损伤。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验